
VERAXA Biotech Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
VERAXA Biotech is presenting partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms, backed by new proof-of-concept data, at the upcoming BIO International Convention, highlighting their potential for tumor-restricted cancer therapy with reduced off-target toxicity.
Read full story





















